hepatitis c

Kratisto Investing: Investopedia: Vertex Building A Fortress In Cystic …

It’s not too often that you see a biotech company establish a truly differentiated product portfolio with multi-billion dollar potential and minimal competition, but Vertex (Nasdaq:VRTX) seems to be doing exactly that. This one-time specialist in virology is already well on the way to more than $5 billion in potential revenue, and could ultimately see nearly double that amount if clinical trials go the right way. This may ultimately put the company in the “nice problem to have” category of figuring out how to reinvest the proceeds and determining whether or not further investments in the hepatitis C program are worthwhile.

Please continue here:

http://www.investopedia.com/stock-analysis/082813/vertex-building-fortress-cystic-fibrosis-vrtx-gild-gsk-bmy.aspx

hepatitis c

via hepatitis c http://hepatitiscweb.blogspot.com/2013/08/kratisto-investing-investopedia-vertex.html

Standard

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s